Solazyme, Inc. (NASDAQ: SZYM), a renewable oil and bioproducts company, announced today that it has been granted registration for SoladieselRD fuel by the U.S. Environmental Protection Agency (EPA). This registration enables SoladieselRD to be sold commercially either in blended and unblended (R100) forms.
"To our knowledge, SoladieselRD is the first 100% microbially based fuel in history to receive an EPA fuel registration for use as a “neat” or unblended product,” said Bob Ames, VP Fuels Commercialization, Solazyme. “Our Soladiesel® and Solajet™ fuels have been extensively demonstrated in a wide array of platforms from cars, light trucks and buses, to commercial and military jets, helicopters, large commercial shipping vessels and Navy destroyers. These higher performing advanced biofuels will lead the path forward to reducing emissions and increasing energy independence. This registration is another key milestone in Solazyme’s mission to commercialize drop-in replacement fuels as we continue to build out our renewable oil production capacity.”
In tests conducted for the EPA registration, SoladieselRD met or exceeded the ASTM D975 specification for conventional diesel fuel. SoladieselRD performed substantially similar to petroleum diesel and even reduced NOX emissions by approximately 10% when tested in modern diesel engines. In a measurement of the combustion quality, SoladieselRD exhibited a Cetane Number greater than 78, which is more than 60 percent better than standard U.S. diesel fuel, indicating SoladieselRD is a high quality fuel.
SoladieselRD is the first algal-derived fuel to be successfully road-tested in blended and unblended (R100) forms for thousands of miles in unmodified vehicles. SoladieselRD is compatible with existing infrastructure and can be used with factory-standard diesel engines without modifications. Solazyme has been involved in a multitude of testing and evaluation partnerships involving our fuels, which range from an integrated testing and certification program with the U.S. Navy, to fuel evaluation programs with Volkswagen and Genentech and commercial use by United Airlines as part of its Eco-Skies program.
About Solazyme, Inc.
Solazyme, Inc. (NASDAQ: SZYM) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources – petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care.
Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization plans and commercialization timetable for SoladieselRD; the attributes of SoladieselRD applications; and the ability of advanced biofuels to reduce emissions and increasing energy independence. When used in this press release, the words "will", "expects", "intends" and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme's limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing and operating commercial manufacturing facilities; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.